Interleukin 10 treatment of psoriasis: Clinical results of a phase 2 trial

Archives of Dermatology

Volumn 135, Issue 2, 1999, Pages 187-192

  Asadullah, Khusru ^a   Döcke, Wolf Dietrich ^a   Ebeling, Merle ^a   Friedrich, Markus ^a   Belbe, Gudrun ^a   Audring, Heike ^a   Volk, Hans Dieter ^a   Sterry, Wolfram ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 10;

ADULT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; FEMALE; HUMAN; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; FEMALE; HUMANS; INTERLEUKIN-10; MALE; MIDDLE AGED; PSORIASIS;

EID: 0345251966     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Christophers E, Sterry W, Psoriasis. In: Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF, eds. Dermatology in General Medicine. New York, NY: McGraw-Hill; 1993:489-515.
2. Valdimarsson H, Baker BS, Johnsdottir I, Fry L. Psoriasis: a disease of abnormal keratinocyte proliferation induced by T lymphocytes. Immunol Today. 1986;7:256-259.
3. Nickoloff BJ. The cytokine network in psoriasis. Arch Dermatol 1991;127:871-884.
4. Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol. 1993;101:701-705
5. Schlaak JF, Buslau M, Jochum W, et al. T cells involved in psoriasis vulgaris belong to the Th 1 subset. J Invest Dermatol. 1994;102:145-149.
6. Krueger JG, Krane JF, Carter DM, Gottlieb AB. Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis. J Invest Dermatol. 1990; 94:135S-140S.
7. Takashima A, Morita A. Genomic, phenotypic, and functional analyses of T cells in patients with psoriasis undergoing systemic cyclosporin A treatment. J Invest Dermatol. 1991;96:376-382.
8. Jegasothy BV, Ackerman CD, Todo S, Fung JJ, Abu-Elmagd K, Starzl TE. Tacrolimus (FK 506). Arch Dermatol 1992;128:781-785.
9. Altmeyer PJ, Matthes U, Pawlak F, et al. Antipsoriatic effect of fumaric acid derivatives. J Am Acad Dermatol. 1994;30:977-981.
10. Asadullah K, Schmid H, Friedrich M, et al. Influence of monomethylfumarate on monocytic cytokine formation. Arch Dermatol Res. 1997;289:623-630.
11. Ohta Y, Katayama I, Funato T, et al. In situ expression of messenger RNA of interleukin-1 and interleukin-6 in psoriasis. Arch Dermatol Res. 1991;283:351-356.
12. Lemster BH, Carroll PB, Rilo HR, Johnson N, Nikaein A, Thomson AW. IL-8/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus (FK506) therapy. Clin Exp Immunol. 1995;99:148-154.
13. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD. Elevated tumor necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol. 1994;96:146-151.
14. Nickoloff BJ, Fivenson DP, Kunkel SL, Strieter RM, Turka LA. Keratinocyte interleukin-10 expression is upregulated in tape-stripped skin, poison ivy dermatitis, and Sezary syndrome, but not in psoriatic plaques. Clin Immunol Immunopathol. 1994;73:63-68.
15. Mussi A, Bonifati C, Carducci M, et al. IL-10 levels are decreased in psoriatic lesional skin as compared to the psoriatic lesion-free and normal skin suction blister fluids. J Biol Regul Homeost Agents. 1994;8:117-120.
16. Asadullah K, Sterry W, Stephanek K, et al. IL-10 is a key cytokine in psoriasis. J Clin Invest. 1998;101:783-794.
17. Kang S, Yi S, Griffiths CEM, Fancher L, Hamilton TA, Choi JH. Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions. Br J Dermatol 1998;138:77-83.
18. Chernoff AE, Granowitz EV, Shapiro L, et al. A randomized, controlled trial of IL-10 in humans. J Immunol. 1995;154:5492-5499.
19. Van Deventer S, Elson CO, Fedorak RN, for the Crohn's Disease Study Group. Multiple dose of intravenous interleukin-10 in steroid refractory Crohn's disease. Gastroenterology. 1997;113:383-389.
20. Wissing KM, Morelon E, Legendre C, et al. A pilot trial of recombinant human interleukin-10 in kidney transplant recipients receiving OKT3 induction therapy. Transplantation. 1997;64:999-1006.
21. Fredriksson T, Pertersson U. Severe psoriasis. Dermatologica. 1978;157:238-244.
22. Romagnani S. Biology of human Th1 and Th2 cells. J Clin Immunol. 1995;15: 121-129.
23. 3 and calcipotriol induce IL-10 receptor gene expression in human epidermal cells. Inflamm Res. 1997;46:32-34.
24. Weinstein GD. Can immunomodulatory molecules work topically for psoriasis? J Invest Dermatol. 1996;106:589.
25. Mitra RS, Judge TA, Nestle FO, Turka LA, Nickoloff BJ. Psoriatic skin-derived dendritic cell function is inhibited by exogenous IL-10: differential modulation of B7-1 (CD80) and B7-2 (CD86) expression. J Immunol. 1995;154:2668-2677.
26. De Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991;174:1209-1220.
27. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol. 1991;147:3815-3822.
28. Norris DA, Traves JB, Leung DYM. Lymphocyte activation in the pathogenesis of psoriasis. J Invest Dermatol. 1997;109:1-4.
29. Becherel PA, LeGoff L, Ktorza S, et al. Interleukin-10 inhibits IgE-mediated nitric oxide synthase induction and cytokine synthesis in normal human keratinocytes. Eur J Immunol. 1995;25:2992-2995.
30. Michel G, Mirmohammadsadegh A, Olasz E, et al. Demonstration and functional analysis of IL-10 receptors in human epidermal cells: decreased expression in psoriatic skin, down-modulation by IL-8, and up-regulation by an antipsoriatic glucocorticosteroid in normal cultured keratinocytes. J Immunol. 1997;159: 6291-6297.